» Articles » PMID: 22423044

Industrial Methodology for Process Verification in Research (IMPROVER): Toward Systems Biology Verification

Overview
Journal Bioinformatics
Specialty Biology
Date 2012 Mar 17
PMID 22423044
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Motivation: Analyses and algorithmic predictions based on high-throughput data are essential for the success of systems biology in academic and industrial settings. Organizations, such as companies and academic consortia, conduct large multi-year scientific studies that entail the collection and analysis of thousands of individual experiments, often over many physical sites and with internal and outsourced components. To extract maximum value, the interested parties need to verify the accuracy and reproducibility of data and methods before the initiation of such large multi-year studies. However, systematic and well-established verification procedures do not exist for automated collection and analysis workflows in systems biology which could lead to inaccurate conclusions.

Results: We present here, a review of the current state of systems biology verification and a detailed methodology to address its shortcomings. This methodology named 'Industrial Methodology for Process Verification in Research' or IMPROVER, consists on evaluating a research program by dividing a workflow into smaller building blocks that are individually verified. The verification of each building block can be done internally by members of the research program or externally by 'crowd-sourcing' to an interested community. www.sbvimprover.com

Implementation: This methodology could become the preferred choice to verify systems biology research workflows that are becoming increasingly complex and sophisticated in industrial and academic settings.

Citing Articles

Results and lessons learned from the sbv IMPROVER metagenomics diagnostics for inflammatory bowel disease challenge.

Khachatryan L, Xiang Y, Ivanov A, Glaab E, Graham G, Granata I Sci Rep. 2023; 13(1):6303.

PMID: 37072468 PMC: 10113391. DOI: 10.1038/s41598-023-33050-0.


The sbv IMPROVER Systems Toxicology Computational Challenge: Identification of Human and Species-Independent Blood Response Markers as Predictors of Smoking Exposure and Cessation Status.

Belcastro V, Poussin C, Xiang Y, Giordano M, Tripathi K, Boda A Comput Toxicol. 2018; 5:38-51.

PMID: 30221212 PMC: 6136260. DOI: 10.1016/j.comtox.2017.07.004.


Human blood gene signature as a marker for smoking exposure: computational approaches of the top ranked teams in the sbv IMPROVER Systems Toxicology challenge.

Tarca A, Gong X, Romero R, Yang W, Duan Z, Yang H Comput Toxicol. 2018; 5:31-37.

PMID: 29556588 PMC: 5856124. DOI: 10.1016/j.comtox.2017.07.003.


How Adverse Outcome Pathways Can Aid the Development and Use of Computational Prediction Models for Regulatory Toxicology.

Wittwehr C, Aladjov H, Ankley G, Byrne H, De Knecht J, Heinzle E Toxicol Sci. 2016; 155(2):326-336.

PMID: 27994170 PMC: 5340205. DOI: 10.1093/toxsci/kfw207.


Identification of Genes Discriminating Multiple Sclerosis Patients from Controls by Adapting a Pathway Analysis Method.

Zhang L, Wang L, Tian P, Tian S PLoS One. 2016; 11(11):e0165543.

PMID: 27846233 PMC: 5112852. DOI: 10.1371/journal.pone.0165543.


References
1.
Ioannidis J . Microarrays and molecular research: noise discovery?. Lancet. 2005; 365(9458):454-5. DOI: 10.1016/S0140-6736(05)17878-7. View

2.
Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M . A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004; 351(27):2817-26. DOI: 10.1056/NEJMoa041588. View

3.
Rudick R, Stuart W, Calabresi P, Confavreux C, Galetta S, Radue E . Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006; 354(9):911-23. DOI: 10.1056/NEJMoa044396. View

4.
Lim W, Lyashenko E, Califano A . Master regulators used as breast cancer metastasis classifier. Pac Symp Biocomput. 2009; :504-15. PMC: 2740937. View

5.
Minagar A, Jy W, Jimenez J, Alexander J . Multiple sclerosis as a vascular disease. Neurol Res. 2006; 28(3):230-5. DOI: 10.1179/016164106X98080. View